These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 19640613

  • 21. Induction of heart valve lesions by small-molecule ALK5 inhibitors.
    Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts RR, Heier A.
    Toxicol Pathol; 2011 Oct; 39(6):916-24. PubMed ID: 21859884
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
    Xie HZ, Li LL, Ren JX, Zou J, Yang L, Wei YQ, Yang SY.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):1944-9. PubMed ID: 19254842
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF, Lu T, Zhu T, Jiang YJ, Rao SS, Hu LY, Xin BT, Chen YD.
    Eur J Med Chem; 2009 Mar 01; 44(3):1240-9. PubMed ID: 18947905
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Hähnke V, Hiss JA, Zettl H, Keppner S, Spänkuch B, Schneider P.
    Future Med Chem; 2011 Mar 01; 3(4):415-24. PubMed ID: 21452978
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
    Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M.
    Exp Mol Pathol; 2007 Aug 01; 83(1):39-46. PubMed ID: 17274978
    [Abstract] [Full Text] [Related]

  • 29. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK, Jung SH, Lee HS, Dewang PM.
    Eur J Med Chem; 2009 Feb 01; 44(2):568-76. PubMed ID: 18467006
    [Abstract] [Full Text] [Related]

  • 30. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
    Roth GJ, Heckel A, Brandl T, Grauert M, Hoerer S, Kley JT, Schnapp G, Baum P, Mennerich D, Schnapp A, Park JE.
    J Med Chem; 2010 Oct 28; 53(20):7287-95. PubMed ID: 20919678
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Mohan AV, Park CY, Son JY, Sheen YY, Kim DK.
    Bioorg Med Chem Lett; 2011 Oct 15; 21(20):6049-53. PubMed ID: 21911290
    [Abstract] [Full Text] [Related]

  • 32. Computational approach to the identification of novel Aurora-A inhibitors.
    Morshed MN, Cho YS, Seo SH, Han KC, Yang EG, Pae AN.
    Bioorg Med Chem; 2011 Jan 15; 19(2):907-16. PubMed ID: 21194953
    [Abstract] [Full Text] [Related]

  • 33. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
    Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE.
    Arterioscler Thromb Vasc Biol; 2008 Apr 15; 28(4):665-71. PubMed ID: 18202322
    [Abstract] [Full Text] [Related]

  • 34. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
    Guo C, Zhang C, Li X, Li W, Xu Z, Bao L, Ding Y, Wang L, Li S.
    Bioorg Med Chem Lett; 2013 Nov 01; 23(21):5850-4. PubMed ID: 24055046
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M, Wang H, Scorah N, Lawson JD, Atienza J, Kamran R, Hixon MS, Dougan DR.
    Bioorg Med Chem Lett; 2017 May 01; 27(9):1955-1961. PubMed ID: 28359790
    [Abstract] [Full Text] [Related]

  • 37. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW.
    Eur J Med Chem; 2010 Jun 01; 45(6):2132-40. PubMed ID: 20206418
    [Abstract] [Full Text] [Related]

  • 38. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK, Ghate M, Goel A.
    J Mol Graph Model; 2013 May 01; 42():17-25. PubMed ID: 23507201
    [Abstract] [Full Text] [Related]

  • 39. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Park HJ, Park SJ, Sheen YY, Kim DK.
    Bioorg Med Chem; 2014 May 01; 22(9):2724-32. PubMed ID: 24704197
    [Abstract] [Full Text] [Related]

  • 40. Pyrazolone based TGFbetaR1 kinase inhibitors.
    Guckian K, Carter MB, Lin EY, Choi M, Sun L, Boriack-Sjodin PA, Chuaqui C, Lane B, Cheung K, Ling L, Lee WC.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):326-9. PubMed ID: 19914068
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.